Lyrica

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
28-02-2024
Karakteristik produk Karakteristik produk (SPC)
28-02-2024

Bahan aktif:

pregabalin

Tersedia dari:

Upjohn EESV

Kode ATC:

N03AX16

INN (Nama Internasional):

pregabalin

Kelompok Terapi:

Antiepileptics, , Other antiepileptics

Area terapi:

Epilepsy; Anxiety Disorders; Neuralgia

Indikasi Terapi:

Neuropathic painLyrica is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyLyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised anxiety disorderLyrica is indicated for the treatment of generalised anxiety disorder (GAD) in adults.

Ringkasan produk:

Revision: 61

Status otorisasi:

Authorised

Tanggal Otorisasi:

2004-07-05

Selebaran informasi

                                77
B. PACKAGE LEAFLET
78
PACKAGE LEAFLET: INFORMATION FOR THE USER LYRICA 25 MG HARD CAPSULES, LYRICA 50 MG HARD CAPSULES, LYRICA 75 MG HARD CAPSULES,
LYRICA 100 MG HARD CAPSULES,
LYRICA 150 MG HARD CAPSULES,
LYRICA 200 MG HARD CAPSULES,
LYRICA 225 MG HARD CAPSULES,
LYRICA 300 MG HARD CAPSULES
pregabalin
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU
.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lyrica is and what it is used for
2.
What you need to know before you take Lyrica
3.
How to take Lyrica
4.
Possible side effects
5.
How to store Lyrica
6.
Contents of the pack and other information
1.
WHAT LYRICA IS AND WHAT IT IS USED FOR
Lyrica belongs to a group of medicines used to treat epilepsy,
neuropathic pain and Generalised
Anxiety Disorder (GAD) in adults.
PERIPHERAL AND CENTRAL NEUROPATHIC PAIN:
Lyrica is used to treat long lasting pain caused by damage
to the nerves. A variety of diseases can cause peripheral neuropathic
pain, such as diabetes or shingles.
Pain sensations may be described as hot, burning, throbbing, shooting,
stabbing, sharp, cramping,
aching, tingling, numbness, pins and needles. Peripheral and central
neuropathic pain may also be
associated with mood changes, sleep disturbance, fatigue (tiredness),
and can have an impact on
physical and social functioning and overall quality of life.
EPILEPSY:
Lyrica is used to treat a certain form of epilepsy (partial seizures
with or without secondary
generalisation) in adults. Your doctor will prescribe Lyrica for you
to help treat your epilepsy when
your current treatment is not
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lyrica 25 mg hard capsules
Lyrica 50 mg hard capsules
Lyrica 75 mg hard capsules
Lyrica 100 mg hard capsules
Lyrica 150 mg hard capsules
Lyrica 200 mg hard capsules
Lyrica 225 mg hard capsules
Lyrica 300 mg hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lyrica 25 mg hard capsules
Each hard capsule contains 25 mg of pregabalin.
Lyrica 50 mg hard capsules
Each hard capsule contains 50 mg of pregabalin.
Lyrica 75 mg hard capsules
Each hard capsule contains 75 mg of pregabalin.
_ _
Lyrica 100 mg hard capsules
Each hard capsule contains 100 mg of pregabalin.
Lyrica 150 mg hard capsules
Each hard capsule contains 150 mg of pregabalin.
_ _
Lyrica 200 mg hard capsules
Each hard capsule contains 200 mg of pregabalin.
_ _
Lyrica 225 mg hard capsules
Each hard capsule contains 225 mg of pregabalin.
Lyrica 300 mg hard capsules
Each hard capsule contains 300 mg of pregabalin.
_ _
Excipients with known effect
_ _
Lyrica 25 mg hard capsules
Each hard capsule also contains 35 mg lactose monohydrate.
Lyrica 50 mg hard capsules
Each hard capsule also contains 70 mg lactose monohydrate.
Lyrica 75 mg hard capsules
Each hard capsule also contains 8.25 mg lactose monohydrate.
Lyrica 100 mg hard capsules
Each hard capsule also contains 11 mg lactose monohydrate.
Lyrica 150 mg hard capsules
Each hard capsule also contains 16.50 mg lactose monohydrate.
Lyrica 200 mg hard capsules
Each hard capsule also contains 22 mg lactose monohydrate.
3
Lyrica 225 mg hard capsules
Each hard capsule also contains 24.75 mg lactose monohydrate.
Lyrica 300 mg hard capsules
Each hard capsule also contains 33 mg lactose monohydrate.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Hard capsules
Lyrica 25 mg hard capsules
White marked “VTRS” on the cap and “PGN 25” on the body with
black ink.
Lyrica 50 mg hard capsules
White marked “VTRS” on the cap and “PGN 50” on the body with
black ink. The body is also marked
with a black ban
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 28-02-2024
Karakteristik produk Karakteristik produk Bulgar 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Bulgar 17-03-2023
Selebaran informasi Selebaran informasi Spanyol 28-02-2024
Karakteristik produk Karakteristik produk Spanyol 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Spanyol 17-03-2023
Selebaran informasi Selebaran informasi Cheska 28-02-2024
Karakteristik produk Karakteristik produk Cheska 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Cheska 17-03-2023
Selebaran informasi Selebaran informasi Dansk 28-02-2024
Karakteristik produk Karakteristik produk Dansk 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Dansk 17-03-2023
Selebaran informasi Selebaran informasi Jerman 28-02-2024
Karakteristik produk Karakteristik produk Jerman 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Jerman 17-03-2023
Selebaran informasi Selebaran informasi Esti 28-02-2024
Karakteristik produk Karakteristik produk Esti 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Esti 17-03-2023
Selebaran informasi Selebaran informasi Yunani 28-02-2024
Karakteristik produk Karakteristik produk Yunani 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Yunani 17-03-2023
Selebaran informasi Selebaran informasi Prancis 28-02-2024
Karakteristik produk Karakteristik produk Prancis 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Prancis 17-03-2023
Selebaran informasi Selebaran informasi Italia 28-02-2024
Karakteristik produk Karakteristik produk Italia 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Italia 17-03-2023
Selebaran informasi Selebaran informasi Latvi 28-02-2024
Karakteristik produk Karakteristik produk Latvi 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Latvi 17-03-2023
Selebaran informasi Selebaran informasi Lituavi 28-02-2024
Karakteristik produk Karakteristik produk Lituavi 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Lituavi 17-03-2023
Selebaran informasi Selebaran informasi Hungaria 28-02-2024
Karakteristik produk Karakteristik produk Hungaria 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Hungaria 17-03-2023
Selebaran informasi Selebaran informasi Malta 28-02-2024
Karakteristik produk Karakteristik produk Malta 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Malta 17-03-2023
Selebaran informasi Selebaran informasi Belanda 28-02-2024
Karakteristik produk Karakteristik produk Belanda 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Belanda 17-03-2023
Selebaran informasi Selebaran informasi Polski 28-02-2024
Karakteristik produk Karakteristik produk Polski 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Polski 17-03-2023
Selebaran informasi Selebaran informasi Portugis 28-02-2024
Karakteristik produk Karakteristik produk Portugis 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Portugis 17-03-2023
Selebaran informasi Selebaran informasi Rumania 28-02-2024
Karakteristik produk Karakteristik produk Rumania 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Rumania 17-03-2023
Selebaran informasi Selebaran informasi Slovak 28-02-2024
Karakteristik produk Karakteristik produk Slovak 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Slovak 17-03-2023
Selebaran informasi Selebaran informasi Sloven 28-02-2024
Karakteristik produk Karakteristik produk Sloven 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Sloven 17-03-2023
Selebaran informasi Selebaran informasi Suomi 28-02-2024
Karakteristik produk Karakteristik produk Suomi 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Suomi 17-03-2023
Selebaran informasi Selebaran informasi Swedia 28-02-2024
Karakteristik produk Karakteristik produk Swedia 28-02-2024
Laporan Penilaian publik Laporan Penilaian publik Swedia 17-03-2023
Selebaran informasi Selebaran informasi Norwegia 28-02-2024
Karakteristik produk Karakteristik produk Norwegia 28-02-2024
Selebaran informasi Selebaran informasi Islandia 28-02-2024
Karakteristik produk Karakteristik produk Islandia 28-02-2024
Selebaran informasi Selebaran informasi Kroasia 28-02-2024
Karakteristik produk Karakteristik produk Kroasia 28-02-2024

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen